Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023
Surface Oncology (Nasdaq: SURF) announced promising preclinical data for SRF114, a fully human anti-CCR8 antibody, presented at the AACR Annual Meeting 2023. The research shows that SRF114 induces a pro-inflammatory tumor microenvironment, enhancing anti-tumor activity in mouse models resistant to checkpoint inhibitors. Key findings demonstrate that SRF114 boosts CD8+ T cell expansion and pro-inflammatory cytokine production while selectively depleting CCR8+ regulatory T cells in tumors. This data strengthens the case for SRF114 as a potential best-in-class therapy and supports its Phase 1 clinical trial for advanced solid tumors. The poster presentation includes significant insights into SRF114's role in augmenting immune responses and improving survival in resistant melanoma models.
- SRF114 shows robust anti-tumor activity in checkpoint inhibition-resistant models.
- Therapeutic depletion of CCR8+ Tregs enhances anti-tumor immunity.
- Increased CD8+ effector T cell production and pro-inflammatory cytokines.
- Supports ongoing Phase 1 clinical investigation for advanced solid tumors.
- None.
– New in vivo data show SRF114 promotes a pro-inflammatory tumor microenvironment resulting in robust antitumor activity in mouse models –
CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the presentation of new preclinical data for SRF114, a fully human anti-CCR8 antibody, at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, Florida. The data will be presented in a poster session (abstract #5125) being held today.
“We are highly encouraged by these new preclinical data which indicate that therapeutic depletion of CCR8 positive tumor infiltrating Tregs results in robust anti-tumorigenic activity in both checkpoint inhibition-resistant and checkpoint inhibition-susceptible tumor models,” said Vito Palombella, PhD, chief scientific officer, Surface Oncology. “These data bolster our belief that SRF114 holds the potential to become a best-in-class anti-CCR8 treatment and further support our ongoing Phase 1 clinical investigation of SRF114 in patients with advanced solid tumors.”
Summary of key data
- In human CCR8 knock-in mice, SRF114, a fully human antibody targeting human CCR8, conferred robust anti-tumor activity and reshaped the tumor microenvironment towards a proinflammatory milieu.
- In different in vivo models, SRF114 monotherapy or treatment with a murine surrogate antibody promoted expansion of CD8+ effector T cells and increased the production of pro-inflammatory molecules including IFNγ, TNFα, and granzyme A in a checkpoint-resistant tumor model.
- Anti-CCR8 therapy resulted in depletion of tumor Tregs without impacting peripheral lymphoid Treg cell populations and led to increases in the levels of co-stimulatory molecules CD80 and CD86 in a subset of tumor myeloid cells.
- Anti-CCR8 and anti-PD-1 combination therapy increased tumor immune cell infiltration, cytokine production and improved overall survival in a checkpoint inhibitor resistant melanoma model.
Poster Session Information
Title: Depletion of CCR8+ tumor Treg cells with SRF114 or anti-CCR8 therapy promotes robust antitumor activity and reshapes the tumor microenvironment toward a more pro-inflammatory milieu
Abstract number: 5125
Session category: Immunology
Session title: Combination Immunotherapies 2
Session date and time: Tuesday, April 18, 2023, from 1:30 p.m. to 5:00 p.m. ET
A copy of the poster will be available on the Posters & Publications page of the company’s website following the presentation.
About SRF114
SRF114 is a fully human, afucosylated anti-CCR8 antibody designed to preferentially deplete CCR8+ Treg cells within the tumor microenvironment. In preclinical studies, Surface Oncology has shown that SRF114 induces antibody-dependent cellular cytotoxicity (ADCC) and/or antibody-dependent cellular phagocytosis (ADCP) pathways to deplete intratumoral Treg cells. In addition, SRF114 reduced tumor growth in murine models. These findings support the advancement of SRF114 as a therapeutic candidate that holds the potential to drive anti-tumor immunity in patients.
About Surface Oncology
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned programs; SRF388, a Phase 2 program which targets IL-27, and SRF114 which selectively depletes regulatory T cells in the tumor microenvironment via targeting CCR8. In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562, formerly SRF813; Phase 1). Surface’s novel, investigational cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.
Contact
Scott Young
Vice President, Investor Relations and Corporate Communications
+1 617 865 3250
syoung@surfaceoncology.com
FAQ
What are the key findings from the SRF114 preclinical data presented by Surface Oncology?
When was the SRF114 data presented at the AACR Annual Meeting?
What is the significance of SRF114 in cancer therapy?
What are the next steps for SRF114 following the preclinical results?
How does SRF114 affect the tumor microenvironment?
